TUMOR BOARD

Friday, February7, 2014

7:30 am – 9:00 am

GI Conference Room –9th Floor Penn Tower

Moderators:

Debbie Cohen, MD – David Metz, MD

University of Pennsylvania

Target Audience

This program has been designed for departmental/institutional faculty, fellows, nurses, and allied health professionals in the medical specialties of medicine, renal, gastroenterology, surgery, nuclear medicine, medical oncology, radiation oncology, endocrine and medical genetics.

Educational Objectives

After completing this activity, participants should be able to:

  • Provide state of the art treatments to patients with NET tumors
  • Coordinate care for management of NET patients through a multidisciplinary approach
  • Increase knowledge in complex genetic mutations of NET patients and recognize the value of genetic testing

Accreditation

The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support*

NONE

For more information, please contact

Bonnie Bennett, RN

215-349-5662

xx

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic, Director of CMEandthe peer reviewerZalman Agus, MD, Associate Dean for CME, have disclosed that they have norelevant financial relationships with any commercial interests related to the content of this educational activity.

The following individuals have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity:

Planning Committee Member & Presenter Names

Debbie Cohen, MD / Bonnie Bennett, RN, BSN

Presenter Name

Elizabeth Fox, MD / Jeffrey Mondschein, MD / Ginna Deitrick, MSN / Lauren Fishbein, MD, PhD
Nevana Damjanov, MD / Steve Keefe, MD / Mandeep Dagli, MD / Katherine Nathanson, MD
Katie Fanslau, MS, BSN / Julia Kharlip, MD / Patricia Gambino, RN, MSN / Andrea Strouth, MSW, LSW
Robert Roses, MD / Keith Cengal, MD, PhD / Adam Kaye, MD

The following individuals have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity.

Planning Committee Member & Presenter NameName of Commercial InterestRelationship

David Metz, MDIpsen & AAAPI Grant

NovartisConsultant

Presenter NameName of Commercial InterestRelationship

Michael C. Soulen, MDGuerbet, LLC, BTGConsultant

Merit Medical, NordionClinical Trial

Daniel Pryma, MDMolecular Insight Pharm.Consultant

Advanced Accelerator ApplicationsResearch Funding

Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected

Disclosure of Unapproved Uses of Products

Presenter nameProductInvestigational and/or Off-label Use

David Metz, MDPert, PanidOff-Label Discussion

Michael C. Soulen, MDIntra-arterial chemotherapy & Intra-arterial brachytherapyVarious

Mandeep Dagli, MDLipidol Chemoembolization & SIR spheres RadioembolizationOff-Label